Three-Month Variability of Commonly Evaluated Biomarkers in Clinically Stable COPD
Seon Cheol Park,Narongkorn Saiphoklang,Jonathan Phillips,May-Lin Wilgus,Russell G Buhr,Donald P Tashkin,Christopher B Cooper,Igor Barjaktarevic
DOI: https://doi.org/10.2147/COPD.S396549
2023-07-19
International Journal of COPD
Abstract:Seon Cheol Park, 1, 2 Narongkorn Saiphoklang, 1, 3 Jonathan Phillips, 4 May-Lin Wilgus, 1 Russell G Buhr, 1 Donald P Tashkin, 1 Christopher B Cooper, 1, 5 Igor Barjaktarevic 1 1 Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; 2 Division of Pulmonology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea; 3 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Thammasat University, Pathum Thani, Thailand; 4 Inflammation Discovery Research, Amgen, Thousand Oaks, CA, USA; 5 Exercise Physiology Research Laboratory, Department of Physiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA Correspondence: Igor Barjaktarevic, Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA, Email Introduction: Clinical decisions in chronic obstructive pulmonary disease (COPD) treatment often utilize serially assessed physiologic parameters and biomarkers. To better understand the reliability of these tests, we evaluated changes in commonly assessed biomarkers over 3 months in patients with clinically stable COPD. Methods: We performed an observational prospective cohort study of 89 individuals with clinically stable COPD, defined as no exacerbation history within 3 months of enrollment. Biomarkers included lung function and functional performance status, patient-reported outcomes of symptoms and health status, and blood markers of inflammation. The correlation between testing at baseline and at 3-month follow-up was reported as the intraclass correlation coefficient (ICC). "Outliers" had significant variability between tests, defined as > 1.645 standard deviations between the two measurements. Differences in clinical features between outliers and others were compared. Results: Participants with COPD (n = 89) were 70.5 ± 6.7 years old, 54 (61%) male, had a 40 pack-year smoking history with 24.7% being current smokers, and postbronchodilator forced expiratory volume in one second (FEV 1 ) 62.3 ± 22.7% predicted. The biomarkers with excellent agreement between the initial and the follow-up measurements were FEV 1 (ICC = 0.96), Saint George's Respiratory Questionnaire (SGRQ) (ICC = 0.98), COPD Assessment Test (CAT) (ICC = 0.93) and C-reactive protein (CRP) (ICC = 0.90). By contrast, parameters showing less robust agreement were 6-minute walking distance (ICC = 0.75), eosinophil count (ICC = 0.77), erythrocyte sedimentation rate (ICC = 0.75) and white blood cell count (ICC = 0.48). Individuals with greater variability in biomarkers reported chronic bronchitis more often and had higher baseline SGRQ and CAT scores. Conclusion: Our study evaluated the stability of commonly assessed biomarkers in clinically stable COPD and showed excellent agreement between baseline and three-month follow-up values for FEV 1 , SGRQ, CAT and CRP. Individuals with chronic bronchitis and more symptomatic disease at baseline demonstrated greater variability in 3-month interval biomarkers. Keywords: COPD, biomarkers, stability, repeatability, variability Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation and represents one of the leading causes of morbidity and mortality worldwide. 1 Phenotyping of COPD patients by clinical features and biomarkers can inform decision-making and prognostication. 2 Numerous biomarkers are routinely used to diagnose COPD, evaluate disease severity, and assess response to treatment. However, relatively few studies have focused on the variability of these biomarkers in clinically stable disease. 3,4 Assessing repeatability and reproducibility allows for evaluation of the stability and reliability of measuring methods. Reliability depends on the population in which the measurements are made and not just technical errors with respect to the methodology and the magnitude of the measurement's inherent variability. It is quantified using the intraclass correlation coefficient (ICC), which ranges between zero and one, with a value of one corresponding to zero measurement error and a value of zero meaning that all the variability in measurements is due to measurement error. 5 In order to better understand the reliability of decision-making based on interpretation of biomarker values, we compared th -Abstract Truncated-
respiratory system